Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women

A new HPV-16/18 bivalent vaccine expressed by the Escherichia coli has been proven to be efficacious in adult women. A randomized, immunogenicity noninferiority study of this candidate vaccine was conducted in December 2015 in China. Girls aged 9–14 years were randomized to receive 2 doses at months...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue-Mei, Guo, Meng, Li, Chang-Gui, Chu, Kai, He, Wen-Gang, Zhang, Jing, Gu, Jian-Xiang, Li, Juan, Zhao, Hui, Wu, Xiang-Hong, Lin, BiZhen, Lin, Zhi-Jie, Yao, Xing-Mei, Li, Ya-Fei, Wei, FeiXue, Huang, Yue, Su, Ying-Ying, Zhu, Feng-Cai, Huang, Shou-Jie, Pan, Hui-Rong, Wu, Ting, Zhang, Jun, Xia, Ning-Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science China Press 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223315/
https://www.ncbi.nlm.nih.gov/pubmed/31231780
http://dx.doi.org/10.1007/s11427-019-9547-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223315/
https://www.ncbi.nlm.nih.gov/pubmed/31231780
http://dx.doi.org/10.1007/s11427-019-9547-7

Ejemplares similares